Charles N. York II Sells 52,183 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 52,183 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the transaction, the chief financial officer now owns 225,571 shares of the company’s stock, valued at approximately $4,035,465.19. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Trading Down 2.3 %

Shares of NASDAQ DAWN opened at $17.17 on Friday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07. The company’s 50-day moving average price is $15.45 and its 200 day moving average price is $14.02.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. JPMorgan Chase & Co. upped their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday, April 22nd. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Finally, The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its holdings in Day One Biopharmaceuticals by 8.8% in the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after purchasing an additional 995 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Day One Biopharmaceuticals by 9.7% in the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock valued at $218,000 after purchasing an additional 1,569 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.